U.S. Markets close in 4 hrs 12 mins

Aastrom enrolled first patients in ixCell-DCM Phase 2b trial of ixmyelocel-T

Aastrom Biosciences announced that the first patients have been enrolled in the ixCELL-DCM clinical trial. This Phase 2b study is currently underway in the U.S. to assess the efficacy and safety of ixmyelocel-T in the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy, or ischemic DCM.